What is the loading dose of mi

Asking for Preferences

What is the loading dose for mi

Asking for Preferences
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Here is a summary of loading doses for key drugs used in Myocardial Infarction (MI), pulled from authoritative textbooks (Washington Manual of Medical Therapeutics, Harrison's Principles, Katzung's Pharmacology, and Braunwald's Heart Disease):

Loading Doses in Myocardial Infarction

Antiplatelet Agents

DrugLoading DoseMaintenanceNotes
Aspirin (ASA)162-325 mg (chewed/crushed)75-100 mg/dayNon-enteric-coated, given orally or rectally; chewing improves absorption
Clopidogrel600 mg orally75-150 mg/day300 mg loading for NSTEMI (older regimen); 600 mg preferred for STEMI/PCI. Avoid loading dose in elderly
Prasugrel60 mg orally10 mg/dayMore potent and faster than clopidogrel. Avoid in patients >75 years, <60 kg, or with prior stroke/TIA
Ticagrelor180 mg orally90 mg twice dailyASA dose must not exceed 100 mg/day when used with ticagrelor. Shows mortality benefit over clopidogrel
Cangrelor30 mcg/kg IV bolus4 mcg/kg/min infusionIV P2Y12 inhibitor; FDA-approved for patients undergoing PCI only

Anticoagulants

DrugLoading DoseMaintenanceNotes
Unfractionated Heparin (UFH)60 units/kg IV bolus (max 4,000 units)12 units/kg/hGiven to all patients undergoing PCI and those receiving thrombolytics (except streptokinase)
Enoxaparin (LMWH)30 mg IV bolus1 mg/kg SC q12hDose adjustments needed in renal impairment and elderly

Glycoprotein IIb/IIIa Inhibitors (high-risk ACS/STEMI with large thrombus)

  • Tirofiban and Eptifibatide - used as IV infusions in selected STEMI/high-risk ACS cases, particularly when cangrelor is not available

Key Clinical Notes

  • STEMI: Aspirin + a P2Y12 inhibitor (prasugrel or ticagrelor preferred over clopidogrel) + anticoagulation is the standard upstream therapy before PCI.
  • NSTEMI: Clopidogrel 300 mg loading dose (or ticagrelor 180 mg) + aspirin is commonly used.
  • Cangrelor may replace oral P2Y12 inhibitors in patients who have not received a pre-procedural oral agent.
(Sources: Washington Manual of Medical Therapeutics; Harrison's Principles of Internal Medicine 22nd Ed.; Katzung's Basic and Clinical Pharmacology 16th Ed.; Braunwald's Heart Disease)
This is a shared conversation. Sign in to Orris to start your own chat.